Bellicum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Bellicum Pharmaceuticals

16/05/2022 14:32

* Bellicum Pharmaceuticals Inc  BLCM.OQ  reported a
quarterly
adjusted loss of 25 cents​​ per share for the quarter ended in
March. The lone analyst forecast for the quarter was for a loss
of 67 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Bellicum Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 25 cents​.
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Bellicum Pharmaceuticals Inc shares had fallen by 26.9%
this
quarter and gained 6.0% so far this year.
    * The company reported a quarterly loss of $7.56 million.
    * Wall Street's median 12-month price target for Bellicum
Pharmaceuticals Inc is $5.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 01:32 p.m.  ​All
figures in US dollars unless otherwise stated